27 related articles for article (PubMed ID: 37345611)
1. Expression of microRNAs in the ascites of patients with peritoneal carcinomatosis and peritonitis.
Schindler P; Kupcinskas J; Juzenas S; Skieceviciene J; Salteniene V; Schulz C; Weigt J; Malfertheiner P; Link A
Cancer Cytopathol; 2018 May; 126(5):353-363. PubMed ID: 29360196
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites.
Jung M; Pützer S; Gevensleben H; Meller S; Kristiansen G; Dietrich D
Clin Epigenetics; 2016; 8():24. PubMed ID: 26937257
[TBL] [Abstract][Full Text] [Related]
3. Peritoneoscopy in diagnosis of ascites.
Amarapurkar DN; Kalro RH; Desai HG
J Assoc Physicians India; 1991 Dec; 39(12):933-5. PubMed ID: 1840061
[TBL] [Abstract][Full Text] [Related]
4. EUS-guided paracentesis for the diagnosis of malignant ascites.
Kaushik N; Khalid A; Brody D; McGrath K
Gastrointest Endosc; 2006 Dec; 64(6):908-13. PubMed ID: 17140897
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometry in the diagnosis of peritoneal carcinomatosis.
Both CT; de Mattos AA; Neumann J; Reis MD
Am J Gastroenterol; 2001 May; 96(5):1605-9. PubMed ID: 11374707
[TBL] [Abstract][Full Text] [Related]
6. Factors Affecting Performance of DNA Methylation as a Potential Biomarker in Ascites for Peritonitis and Peritoneal Carcinomatosis.
Bose K; Scurt FG; Thon C; Franke S; Schulz C; Malfertheiner P; Link A
J Gastrointestin Liver Dis; 2023 Jun; 32(2):206-215. PubMed ID: 37345611
[TBL] [Abstract][Full Text] [Related]
7. The laparoscopic evaluation of ascites.
Inadomi JM; Kapur S; Kinkhabwala M; Cello JP
Gastrointest Endosc Clin N Am; 2001 Jan; 11(1):79-91. PubMed ID: 11175976
[TBL] [Abstract][Full Text] [Related]
8. Bacterial peritonitis in a patient with malignant ascites caused by pancreatic carcinoma: Case report and review of literature.
Miyashita H; Okamoto K; Kobayashi T; Wakabayashi Y; Kitaura S; Ikeuchi K; Ishigaki K; Nakai Y; Okugawa S; Koike K; Moriya K
J Infect Chemother; 2019 Jun; 25(6):473-476. PubMed ID: 30738726
[TBL] [Abstract][Full Text] [Related]
9. Malignancy-related ascites and ascitic fluid "humoral tests of malignancy".
Runyon BA
J Clin Gastroenterol; 1994 Mar; 18(2):94-8. PubMed ID: 8189030
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal mesothelioma in recurrent familial peritonitis.
Gentiloni N; Febbraro S; Barone C; Lemmo G; Neri G; Zannoni G; Capelli A; Gasbarrini G
J Clin Gastroenterol; 1997 Jun; 24(4):276-9. PubMed ID: 9252860
[TBL] [Abstract][Full Text] [Related]
11. A Palliative Approach to Management of Peritoneal Carcinomatosis and Malignant Ascites.
Bleicher J; Lambert LA
Surg Oncol Clin N Am; 2021 Jul; 30(3):475-490. PubMed ID: 34053663
[TBL] [Abstract][Full Text] [Related]
12. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
Ströhlein MA; Heiss MM
Future Oncol; 2010 Sep; 6(9):1387-94. PubMed ID: 20919824
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
